Hsv Infection
Hsv Infection - Related Videos
02:48
Labeling of Replicating HSV-1 Genomes with a Nucleoside Analog
0 Views •
2026
Source: Dembowski, J. A., Deluca, N. A. Purification of Viral DNA for the Identification of Associated Viral and Cellular Proteins. J. Vis. Exp. (2017)This video demonstrates the infection of stationary-phase mammalian cells with HSV-1 (Herpes Simplex Virus-1), followed by replication of the viral genome using host and viral replication machinery. A synthetic nucleoside analog is incorporated into newly synthesized viral DNA to label replicating genomes, which are subsequently isolated for...
07:30
HSV-Mediated Transgene Expression of Chimeric Constructs to Study Behavioral Function of GPCR Heteromers in Mice
0 Views •
Cited by 8 •
2016
This article describes how to inject viral vectors into the mouse frontal cortex to test behavioral assays that require GPCR heteromeric formation.
12:33
Determination of Biofilm Initiation on Virus-infected Cells by Bacteria and Fungi
0 Views •
Cited by 3 •
2016
A method is described herein for the determination of inter-Kingdom association and competition (bacterial and fungal) for adherence to virus-infected HeLa cell monolayers. This protocol can be extended to multiple combinations of prokaryotes, eukaryotes, and viruses.
11:56
Ex Vivo Infection of Murine Epidermis with Herpes Simplex Virus Type 1
0 Views •
Cited by 15 •
2015
The skin is one target tissue of the human pathogen herpes simplex virus type 1 (HSV-1). To explore the invasion route of HSV-1 into tissue, we established an ex vivo infection model of murine epidermal sheets which represent the outermost layer of skin.
09:15
Tyramide Signal Amplification for the Immunofluorescent Staining of ZBP1-Dependent Phosphorylation of RIPK3 and MLKL After HSV-1 Infection in Human Cells
0 Views •
Cited by 1 •
2022
Tyramide signal amplification during immunofluorescent staining enables the sensitive detection of phosphorylated RIPK3 and MLKL during ZBP1-induced necroptosis after HSV-1 infection.
FAQs
Entry and persistence occur in different cellular settings. Following epithelial-cell fusion, HSV delivers its double-stranded DNA genome to the nucleus for replication, then travels along sensory neurons, where it remains latent rather than continually producing lesions. This separation helps explain why treatment and immune responses must address both active replication and long-term neuronal persistence.
Reactivation reflects a change in the balance between viral persistence and host control. Stress, illness, or immune changes can trigger HSV to leave its latent state, resume activity, and produce recurrent lesions. These triggers make recurrence a useful context for studying how environmental or physiological changes influence infection without requiring a new exposure.
Viral immune evasion and host inflammation represent complementary research questions. Evasion helps explain how HSV persists despite immune defenses, whereas inflammatory responses help explain how the host reacts to infection. Examining both processes can connect molecular viral behavior with clinical outcomes and guide strategies intended to limit recurrence or complications.
Diagnostic testing translates knowledge of HSV infection into an approach for identifying infection and evaluating disease-related findings. It is especially important because HSV can persist latently and later reactivate, creating different biological states to assess. In research and care, testing supports evaluation of transmission, recurrence, complications, and responses to antiviral treatment.
Antiviral treatment addresses the replicative phase that follows delivery of the viral genome to the nucleus. Research on HSV replication and persistence can therefore identify when treatment may reduce active disease, while latency explains why treatment alone may not eliminate lifelong infection. This distinction helps frame studies of recurrence control and therapeutic limitations.
Immunocompromised patients are a key context because weakened immune control may alter the balance between viral persistence, reactivation, and inflammatory responses. HSV research uses this context to examine why complications can become more important when host defenses are impaired. The resulting knowledge can support treatments designed to reduce complications in these patients.
Vaccine and therapy research aims beyond treating individual lesions. By examining entry, replication, latency, immune evasion, and inflammation, investigators can seek interventions that reduce transmission, recurrence, or complications. These goals reflect the central challenge of HSV infection: controlling a virus that can persist in the host and reactivate after its initial episode.